Search

Search bills, members, committees and pages...

Sign In

BOEHRINGER INGELHEIM USA CORPORATION

PreviousNext

50 federal lobbying filings, 2023 to 2026.

BOEHRINGER INGELHEIM USA CORPORATION is a client on 50 federal lobbying filings, 2023 to 2026, reporting $1M across them. Pharmaceutical manufacturer. Based in District of Columbia.

An LDA filing reports one registrant’s income from one client for everything they worked that quarter, so a total here is the sum of whole filings and never a price for one issue or one bill.

Firms

4 it has hired, by filings.

RegistrantFilingsReported
BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC17—
HANCE SCARBOROUGH14$280K
MONUMENT ADVOCACY14$700K
BLUEBIRD STRATEGIES5$60K

By year

Filings and what they reported, newest year first.

YearFilingsIncomeExpenses
20266$140K$1.9M
202514$280K$5.2M
202413$300K$4.5M
202317$320K$5.9M

Issues

The LDA issue codes the filings were filed under.

CodeIssueFilings
ANIAnimals31
BUDBudget/Appropriations31
AGRAgriculture28
MMMMedicare/Medicaid22
HCRHealth Issues17
PHAPharmacy14
DEFDefense4
TRDTrade (domestic/foreign)3

Bills

The bills the filings name, by how many name them.

BillTitleFilings
H.R. 1492To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and bi…8
S. 832EPIC Act of 20258
H.R. 8467ZOMBIE Act7
H.R. 1842PAW Act of 20255
H.R. 3419To amend the Public Health Service Act to reauthorize the telehealth network and telehealth resource centers…4
H.R. 842Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act4
H.R. 946ORPHAN Cures Act4
S. 1666Improving Social Security’s Service to Victims of Identity Theft Act4
S. 1862ORPHAN Cures Act4
S. 339A bill to amend title XVIII of the Social Security Act to provide for Medicare coverage of multi-cancer early…4
H.R. 7567Farm, Food, and National Security Act of 20262
H.R. 5371Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and E…1

Lobbyists

Named on the filings.

LobbyistClientsFilings
KATHARINE BOND117
SARAH NORDSTROM117
BILL DAVIS116
DAMON WELLS114
JOHN WEBER114
LILIA HORDER114
THOMAS HAWKS114
SCOTT BENNETT112
CHRISTOPHER CUNNINGHAM111
POORVIE BISHNOI111
MARY WALSH19
JOHN BRENNAN15
JULIAN MALASI13
RYAN DONNELLY13
WILLIAM DENT12
ALEXA FOX11

Filings

The documents themselves, on the Senate’s Lobbying Disclosure site, newest first.

ClientRegistrantPeriodReportedPosted
BOEHRINGER INGELHEIM USA CORPORATIONBOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC2026 second_quarter$710KJul 20, 2026
BOEHRINGER INGELHEIM USA CORPORATIONMONUMENT ADVOCACY2026 second_quarter$50KJul 20, 2026
BOEHRINGER INGELHEIM USA CORPORATIONHANCE SCARBOROUGH2026 second_quarter$20KJul 17, 2026
BOEHRINGER INGELHEIM USA CORPORATIONBOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC2026 first_quarter$1.2MApr 20, 2026
BOEHRINGER INGELHEIM USA CORPORATIONMONUMENT ADVOCACY2026 first_quarter$50KApr 20, 2026
BOEHRINGER INGELHEIM USA CORPORATIONHANCE SCARBOROUGH2026 first_quarter$20KApr 18, 2026
BOEHRINGER INGELHEIM USA CORPORATIONBOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC2025 second_quarter$990KMar 10, 2026
BOEHRINGER INGELHEIM USA CORPORATIONBOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC2025 fourth_quarter$610KFeb 4, 2026
BOEHRINGER INGELHEIM USA CORPORATIONBOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC2025 fourth_quarter$580KJan 20, 2026
BOEHRINGER INGELHEIM USA CORPORATIONHANCE SCARBOROUGH2025 fourth_quarter$20KJan 20, 2026
BOEHRINGER INGELHEIM USA CORPORATIONMONUMENT ADVOCACY2025 fourth_quarter$50KJan 20, 2026
BOEHRINGER INGELHEIM USA CORPORATIONBOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC2025 third_quarter$820KOct 20, 2025
BOEHRINGER INGELHEIM USA CORPORATIONMONUMENT ADVOCACY2025 third_quarter$50KOct 20, 2025
BOEHRINGER INGELHEIM USA CORPORATIONHANCE SCARBOROUGH2025 third_quarter$20KOct 17, 2025
BOEHRINGER INGELHEIM USA CORPORATIONHANCE SCARBOROUGH2025 second_quarter$20KJul 21, 2025
BOEHRINGER INGELHEIM USA CORPORATIONBOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC2025 second_quarter$990KJul 21, 2025
BOEHRINGER INGELHEIM USA CORPORATIONMONUMENT ADVOCACY2025 second_quarter$50KJul 21, 2025
BOEHRINGER INGELHEIM USA CORPORATIONBOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC2025 first_quarter$1.2MApr 21, 2025
BOEHRINGER INGELHEIM USA CORPORATIONHANCE SCARBOROUGH2025 first_quarter$20KApr 21, 2025
BOEHRINGER INGELHEIM USA CORPORATIONMONUMENT ADVOCACY2025 first_quarter$50KApr 21, 2025
BOEHRINGER INGELHEIM USA CORPORATIONMONUMENT ADVOCACY2024 fourth_quarter$50KJan 21, 2025
BOEHRINGER INGELHEIM USA CORPORATIONBOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC2024 fourth_quarter$850KJan 21, 2025
BOEHRINGER INGELHEIM USA CORPORATIONHANCE SCARBOROUGH2024 fourth_quarter$20KJan 18, 2025
BOEHRINGER INGELHEIM USA CORPORATIONBOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC2024 third_quarter$1.2MOct 22, 2024
BOEHRINGER INGELHEIM USA CORPORATIONMONUMENT ADVOCACY2024 third_quarter$50KOct 21, 2024